GLP-1受体激活剂和非关节炎前面缺血光学神经病变:内分泌学家需要知道的内容
Livia Liu1, Sharanya Mohan1, Linda Wu1,2,3
1Department of Endocrinology, Concord Repatriation General Hospital, Sydney 2137, Australia.
The Journal of clinical endocrinology and metabolism
|September 29, 2025
概括
类似葡萄糖-1受体激动剂 (GLP-1RA) 可能与非动脉炎前部缺血性视觉神经病变 (NAION) 相关,尽管绝对风险较低. 需要进一步的研究来确定内分泌学家的高风险患者.
科学领域:
- 内分泌学 在内分泌学.
- 眼科医生 眼科 眼科
- 药理学 药理学是指药理学的学科.
背景情况:
- 新出现的证据表明,葡萄糖类-1受体激动剂 (GLP-1RA) 和非动脉炎前部缺血性视神经病变 (NAION) 之间存在潜在联系.
- 追溯研究表明,GLP-1 RA使用可能会增加NAION的风险,危险比率从2.19到7.74.
研究的目的:
- 探索目前关于与GLP-1 RA在2型糖尿病和肥胖患者中的使用相关的NAION风险的研究.
- 分析可能增加对NAION敏感性的患者特异性因素.
- 确定未来研究的领域,以指导内分泌学家在处方GLP-1RA时.
主要方法:
- 审查现有的回顾性队列研究和当前文献.
- 在GLP-1 RA治疗的背景下,对NAION患者特征和潜在风险因素的分析.
主要成果:
- 目前的证据表明GLP-1 RA启动和NAION之间可能存在关联.
- 尽管存在潜在的关联,但NAION的绝对风险似乎很低.
结论:
- 需要权衡GLP-1RA的潜在益处与NAION的低绝对风险.
- 需要进一步的研究来确定特定的患者特征 (例如,光盘参数,血压,体重减轻,血糖控制),这可能表明NAION的风险更高.
相关概念视频
Open Angle Glaucoma: Treatment
963
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
963
Glucagon-like Receptor Agonists
848
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
848
Angle Closure Glaucoma: Treatment
1.2K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.2K
Glaucoma: Overview
1.2K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.2K
Oral Hypoglycemic Agents: Glinides
600
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
600
Dipeptidyl Peptidase 4 Inhibitors
594
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
594


